IRIS
BEZZIO, Cristina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.289
NA - Nord America 1.057
EU - Europa 243
SA - Sud America 227
AF - Africa 30
OC - Oceania 2
Totale 2.848
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.004
SG - Singapore 769
CN - Cina 232
BR - Brasile 181
VN - Vietnam 122
IT - Italia 57
HK - Hong Kong 48
DE - Germania 36
IN - India 32
FR - Francia 30
CA - Canada 26
MX - Messico 21
GB - Regno Unito 20
BD - Bangladesh 19
FI - Finlandia 15
IE - Irlanda 14
NL - Olanda 14
AR - Argentina 13
EC - Ecuador 12
RU - Federazione Russa 12
ES - Italia 9
ZA - Sudafrica 8
PK - Pakistan 7
AT - Austria 6
LT - Lituania 6
TR - Turchia 6
AE - Emirati Arabi Uniti 5
CO - Colombia 5
IQ - Iraq 5
JO - Giordania 5
JP - Giappone 5
PE - Perù 5
PL - Polonia 5
ID - Indonesia 4
MA - Marocco 4
NG - Nigeria 4
NP - Nepal 4
PY - Paraguay 4
SA - Arabia Saudita 4
TN - Tunisia 4
CL - Cile 3
CZ - Repubblica Ceca 3
IL - Israele 3
IR - Iran 3
KE - Kenya 3
LV - Lettonia 3
PS - Palestinian Territory 3
UZ - Uzbekistan 3
BE - Belgio 2
CH - Svizzera 2
CI - Costa d'Avorio 2
EG - Egitto 2
HN - Honduras 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MY - Malesia 2
SE - Svezia 2
VE - Venezuela 2
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
KH - Cambogia 1
LU - Lussemburgo 1
ML - Mali 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
TW - Taiwan 1
UY - Uruguay 1
Totale 2.848
Salva come PNG Salva come JPEG
Città #
Singapore 326
Ashburn 198
San Jose 178
The Dalles 108
Shanghai 64
Chandler 57
Beijing 56
Hong Kong 44
Los Angeles 40
Ho Chi Minh City 38
Dallas 37
Santa Clara 37
Hanoi 30
Boardman 23
Milan 21
Buffalo 18
New York 18
Helsinki 15
Dublin 14
Mexico City 14
São Paulo 14
Montreal 13
Lawrence 10
Princeton 10
London 9
Orem 9
Seattle 9
Secaucus 9
Amsterdam 8
Chennai 8
Düsseldorf 8
Brooklyn 7
Da Nang 7
Frankfurt am Main 7
Rome 7
Wilmington 7
Quito 6
Amman 5
Rio de Janeiro 5
San Francisco 5
Toronto 5
Benin City 4
Curitiba 4
Dubai 4
Johannesburg 4
Munich 4
Paris 4
Porto Alegre 4
Portsmouth 4
San Mateo 4
Warsaw 4
Belo Horizonte 3
Brasília 3
Chandigarh 3
Chicago 3
Council Bluffs 3
Dhaka 3
Guayaquil 3
Irsina 3
Lima 3
Limeira 3
Madrid 3
Mumbai 3
Nairobi 3
Ninh Bình 3
Phoenix 3
Pune 3
São Bernardo do Campo 3
Taiyuan 3
Tashkent 3
Thái Bình 3
Tokyo 3
Valencia 3
Abidjan 2
Ann Arbor 2
Asunción 2
Atlanta 2
Bishkek 2
Boston 2
Bruino 2
Brussels 2
Campinas 2
Caxias do Sul 2
Concord 2
Cuiabá 2
Edison 2
Falkenstein 2
Fortaleza 2
Foz do Iguaçu 2
Guarulhos 2
Hai Bà Trưng 2
Hillsboro 2
Houston 2
Itabira 2
Jacksonville 2
Jeddah 2
Karachi 2
Kuala Lumpur 2
Lambaré 2
Lauterbourg 2
Totale 1.664
Salva come PNG Salva come JPEG
Nome #
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 98
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 87
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 74
The learning curve for using intestinal ultrasonography 71
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 67
Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm? 65
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study 63
Factors correlated with transmural healing in patients with Crohn's disease in long-term clinical remission on anti-TNF medication 62
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 61
Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study 60
Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study 56
Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease 53
Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons 53
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease 52
The Impact of Ustekinumab Biosimilar on Therapeutic Strategies in Crohn's Disease: A Paradigm Shift? 52
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 51
Exploring the link: Porto-sinusoidal vascular disorder and inflammatory bowel disease – A comprehensive narrative review 51
Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational Study 50
Nutritional care at centres managing patients with inflammatory bowel disease: A nationwide survey in Italy 48
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy 48
Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections 48
Efficacy of a novel self-assembling peptide hemostatic gel as rescue therapy for refractory acute gastrointestinal bleeding 48
Reporting of Magnetic Resonance Enterography in Inflammatory Bowel Disease: Results of an Italian Survey 48
Ophthalmological Manifestations in Inflammatory Bowel Diseases: Keep an Eye on It 46
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 46
Noninvasive Assessment of Postoperative Disease Recurrence in Crohn’s Disease: A Multicenter, Prospective Cohort Study on Behalf of the Italian Group for Inflammatory Bowel Disease 45
The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus 45
Hold the Foam : Why Topical Budesonide Remains Relevant for IBD Therapy 45
Ultrasonography Tight Control and Monitoring in Crohn’s Disease During Different Biological Therapies: A Multicenter Study 44
Unmet needs of Italian physicians managing patients with inflammatory bowel disease 44
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study 44
Biologic Therapies May Reduce the Risk of COVID-19 in Patients With Inflammatory Bowel Disease 44
Efficacy, safety and tolerability, the imperfect triangle arising from the new low volume colon preparations 43
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study 42
Planning phase two for endoscopic units in Northern Italy after the COVID-19 lockdown: An exit strategy with a lot of critical issues and a few opportunities 41
Eosinophils, Eosinophilic Gastrointestinal Diseases, and Inflammatory Bowel Disease: A Critical Review 41
Prevalence, Risk Factors and Association with Clinical Outcomes of Malnutrition and Sarcopenia in Inflammatory Bowel Disease: A Prospective Study 41
IBD Flare in the COVID-19 Pandemic:Therapy Discontinuation Is to Blame 40
Endoscopic ultrasound-guided gallbladder drainage in pancreatic cancer and cholangitis: A case report 40
Gastrointestinal ultrasound in inflammatory bowel disease: Seeing beyond limits 39
Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A Single-Center Cohort Study 38
Impact of histologic disease activity on long-term outcomes in patients with ileal pouch-anal anastomosis for ulcerative colitis 38
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 38
Management of proctitis in ulcerative colitis and the place of biological therapies 38
Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study 38
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology 37
Does ProCore fine needle biopsy really improve the clinical outcome of endoscopic ultrasound-guided sampling of pancreatic masses? 36
Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey 36
Neuroendocrine tumors in patients with inflammatory bowel disease: a case series 35
Improvement in appropriateness and diagnostic yield of fast-track endoscopy during the COVID-19 pandemic in Northern Italy 34
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy 34
Severe Inflammatory Bowel Disease Flares and COVID-19: Expand the Gastroenterology–Surgery Team to Include an Infectious Disease Specialist 33
Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds 32
Management of Post-Operative Crohn’s Disease: Knowns and Unknowns 32
Ulcerative colitis: Not only gut 32
Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population 29
Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies 28
Collecting and Analyzing IBD Clinical Data for Machine-Learning: Insights from an Italian Cohort 27
Inflammatory bowel disease in a colorectal cancer screening population: Diagnosis and follow-up 27
Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study 26
Proposal for returning to routine endoscopy during the COVID-19 pandemic: what is really feasible? 24
Upadacitinib in Patients With Difficult-to-Treat Crohn’s Disease 22
A multicenter study on bowel preparation in inflammatory bowel disease patients: comparison between 1L-PEG-ASC and 2L-PEG regimens in an outpatient setting 12
Combining Advanced Targeted Therapy in Inflammatory Bowel Disease: Current Practice and Future Directions 11
Building a Robust Investigator-Initiated Platform: The I-CARE Experience 11
Attitudes of physicians managing inflammatory bowel disease toward alterations of liver function tests: an Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) survey 11
Drug Development in Inflammatory Bowel Diseases: What Is Next? 9
Sessile Serrated Lesions in Inflammatory Bowel Disease: Hidden Players in Colitis-Associated Colorectal Cancer? 9
Revolutionizing Crohn's disease monitoring: The emerging role of intestinal ultrasound 6
Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations 5
Protein-losing enteropathy in inflammatory bowel diseases 4
Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study 3
Letter: immune-mediated inflammatory diseases and inflammatory bowel disease-are we ready for a Copernican revolution? 3
Extracellular Vesicle-Enclosed Oxidative Stress- and Inflammation-Related microRNAs as Potential Biomarkers of Vitamin D Responsivity: A Pilot Study on Inflammatory Bowel Disease Patients with or without COVID-19 3
Upper Gastrointestinal Crohn’s Disease: Shedding Light on the Obscure L4 Classification Meaning 3
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation 3
Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort Study 3
Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review 3
Digital biomarkers and artificial intelligence: a new frontier in personalized management of inflammatory bowel disease 3
The impact of biologic therapies on extra-intestinal manifestations in inflammatory bowel disease: A multicenter study 3
Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis 2
New horizons in the imaging of perianal Crohn’s disease: transperineal ultrasonography 2
Insights into the role of gastrointestinal ultrasound in ulcerative colitis 2
Upadacitinib is Associated With Better Clinical and Biochemical Outcomes Than Tofacitinib in Refractory, Moderate-to-severe Ulcerative Colitis 2
TL1A as a Target in Inflammatory Bowel Disease: Exploring Mechanisms and Therapeutic Potential 2
Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study 2
Continuous clinical remission with biologics in ulcerative colitis: the ‘AURORA’ comparison study 2
Sustainable monitoring in inflammatory bowel disease: comparative carbon, energy, waste, and cost impact of intestinal ultrasound versus colonoscopy 2
Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn’s Disease 2
Tolerability of Bowel Preparation and Colonoscopy in IBD Patients: Results From a Prospective, Single-Center, Case–Control Study 2
Ulcerative colitis: current pharmacotherapy and future directions 2
Transient small-bowel intussusceptions in adults: significance of ultrasonographic detection 2
Learning Curve in Intestinal Ultrasound: Advancing from Basic Skills to Advanced Competencies–Insights from the IUS IG-IBD Master Program 2
Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: Risk Management and Surveillance Strategies 1
Is it time to introduce health coaching in inflammatory bowel disease management? 1
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 1
Splanchnic Hemodynamics and Intestinal Vascularity in Crohn's Disease: An In Vivo Evaluation Using Doppler and Contrast-Enhanced Ultrasound and Biochemical Parameters 1
Prevalence of Disease-Related Malnutrition and Micronutrients Deficit in Patients with Inflammatory Bowel Disease: A Multicentric Cross-Sectional Study by the GSMII (Inflammatory Bowel Disease Study Group) 1
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 1
Abdominal pain after minor trauma in a patient with Crohn's disease 1
Totale 2.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.809
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.809
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 0 1
2021/202210 0 0 0 3 0 0 0 1 1 0 4 1
2022/2023138 21 2 11 20 11 16 0 13 21 13 8 2
2023/2024184 3 11 23 6 2 8 8 4 0 39 34 46
2024/2025729 7 7 20 17 6 47 47 70 130 169 102 107
2025/20261.908 228 95 71 158 118 120 464 92 135 135 197 95
Totale 2.983